Alerts will be sent to your verified email
Verify EmailCIPLA
|
Cipla
|
Zydus Lifesciences
|
Lupin
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Number of ANDA's Filed in USA
|
285.0 . | 508.0 . | 430.0 . |
|
Number of ANDA's Approved By USFDA
|
230.0 . | 435.0 . | 344.0 . |
|
Domestic Sales Growth - YoY
|
10.9 % | 14.5 % | 12.1 % |
|
US DMF Filings
|
2824.0 . | 147.0 . | 94.0 . |
|
R&D as a % of Total Sales
|
7.8 % | 9.2 % | 7.5 % |
|
Financials
|
|||
|
5 yr Average ROE
|
13.53 % | 18.91 % | 8.95 % |
|
5yr average Equity Multiplier
|
1.22 | 1.54 | 1.73 |
|
5yr Average Asset Turnover Ratio
|
0.77 | 0.64 | 0.75 |
|
5yr Avg Net Profit Margin
|
14.55 % | 19.77 % | 5.06 % |
|
Price to Book
|
3.38 | 4.17 | 5.03 |
|
P/E
|
29.96 | 22.44 | 21.17 |
|
5yr Avg Cash Conversion Cycle
|
-6.65 Days | -82.46 Days | -84.38 Days |
|
Inventory Days
|
57.59 Days | 35.53 Days | 53.32 Days |
|
Days Receivable
|
52.05 Days | 33.55 Days | 51.23 Days |
|
Days Payable
|
107.59 Days | 152.05 Days | 169.09 Days |
|
5yr Average Interest Coverage Ratio
|
68.84 | 30.63 | 7.04 |
|
5yr Avg ROCE
|
19.16 % | 20.3 % | 10.02 % |
|
5yr Avg Operating Profit Margin
|
22.76 % | 25.0 % | 14.15 % |
|
5 yr average Debt to Equity
|
0.02 | 0.18 | 0.3 |
|
5yr CAGR Net Profit
|
9.04 % | 2.35 % | n/a |
|
5yr Average Return on Assets
|
11.12 % | 12.36 % | 3.91 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
29.21 % | 75.01 % | 46.86 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-4.34 % | 0.03 % | -0.22 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
3.66 % | -0.68 % | -0.03 % |
|
Cipla
|
Zydus Lifesciences
|
Lupin
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
Therapeutic Area Wise Break-Up - Domestic
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
-
|